Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $71.55 USD
Change Today +2.82 / 4.10%
Volume 850.0
AZNCF On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZNCF) Snapshot

Open
$72.15
Previous Close
$68.73
Day High
$72.15
Day Low
$70.85
52 Week High
05/1/14 - $81.70
52 Week Low
03/11/15 - $64.65
Market Cap
90.4B
Average Volume 10 Days
148.1
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
--
Dividend
$3.11
Dividend Yield
4.35%
Current Stock Chart for ASTRAZENECA PLC (AZNCF)

astrazeneca plc (AZNCF) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZNCF) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZNCF) Key Developments

Astrazeneca Announces Positive Clinical Trial Evidence for its Investigational Non-Small-Cell Lung Cancer Treatment AZD9291

AstraZeneca announced on 17 April positive clinical trial evidence for its investigational non-small-cell lung cancer (NSCLC) treatment AZD9291. The company reported that AZD9291, which is currently studied in the Phase I/II AURA study, showed a median progression free survival of 13.5 months in NSCLC patients with advanced epidermal growth factor receptor mutation-positive who also have the T790M resistance mutation. Data were presented at the European Lung Cancer Conference 2015.

US Food and Drug Administration Grants AstraZeneca's MEK Inhibitor Selumetinib

AstraZeneca announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma. Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye. It is the most common primary intraocular malignancy in adults and comprises 5% of all melanomas. The Orphan Drug Designation programme provides orphan status to drugs and biologics, which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Selumetinib, originally licensed from Array BioPharma Inc., inhibits the MEK pathway in cancer cells to prevent the tumour from growing. Data from a phase III study evaluating selumetinib in combination with chemotherapy in patients with first-line metastatic uveal melanoma is expected to be available later this year. In addition to uveal melanoma, selumetinib is being investigated in Phase III studies in KRAS mutation positive lung cancer and thyroid cancer and in Phase II in children with neurofibromatosis Type 1.

AstraZeneca PLC, Immunocore Ltd Enters Collaboration Agreement Focused on Immuno-Oncology Clinical Trials

AstraZeneca PLC announced it was strengthening its relationship with Immunocore Ltd. through a collaboration agreement focused on immuno-oncology clinical trials. AstraZeneca is party to the agreement via its biologics R&D arm MedImmune. The terms of the new deal call for Immunocore to conduct a Phase Ib/II clinical trial combining its lead T-cell receptor-based investigational therapeutic IMCgp100 with MedImmune's investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4). MedImmune and Immunocore have an exclusive arrangement for the development of IMCgp100 in combination with MEDI4736 and/or tremelimumab. MedImmune will have first right of negotiation for the future commercial development of these combinations for tumours expressing glycoprotein 100 (gp100).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $71.55 USD +2.82

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.29 USD -0.30
BASF SE €89.06 EUR -2.39
Biogen Inc $419.44 USD -9.21
Celgene Corp $113.47 USD -2.89
Eli Lilly & Co $72.47 USD -1.02
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 72.9x
Price/Sales 3.4x
Price/Book 4.6x
Price/Cash Flow 72.8x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.